Copyright
©The Author(s) 2017.
World J Hematol. Aug 6, 2017; 6(3): 32-54
Published online Aug 6, 2017. doi: 10.5315/wjh.v6.i3.32
Published online Aug 6, 2017. doi: 10.5315/wjh.v6.i3.32
The 1980 RCP criteria for prefibrotic ET[37,52] | |
Major criteria | |
A1 | Persistent platelet count in excess of 400 × 109/L |
A2 | Increase and clustering of enlarged megakaryocytes in bone marrow biopsy |
A3 | No or slight increase of reticulin fibers (RF 0 or RF 1) |
Confirmative criteria | |
B1 | Presence of large platelets in a peripheral blood smear |
B3 | No or slight splenomegaly on ultrasound sonography (length diameter normal value < 12 cm) |
B4 | Increase of LAP-score and no signs of fever or inflammation |
Exclusion criterion | |
Ph+ chromosome and any other cytogenetic abnormality in blood or bone marrow nucleated cells | |
The 1980 RCP criteria for prefibrotic PV to replace the crude 1975 PVSG criteria for PV | |
Major | |
A1 | The combination of erythrocyte count of > 6 × 1012/L and bone marrow hypercellularity due to EM or EMG hyperproliferation is pathognomonic diagnostic for PV (Dameshek and Henthel[27] 1940, Dameshek[38] 1950, Kurnike et al[39] 1972) obviating the need to measure raised red cell mass |
A2 | Increase in bone marrow biopsy of clustered, enlarged pleomorphic megakaryocytes with hyperlobulated nuclei and moderate to marked increase cellularity of megakaryopoiesis/erythropoiesis or typically trilinear mega-erythro-granulopoiesis (EMG). Such a typical PV bone marrow picture excludes all variant of primary and secondary erythrocytosis[37-39] |
Minor | |
B1 | Thrombocythemia, persistant increase of platelet > 400 × 109/L |
B2 | Leukocytosis, leucocyte count > 109/L and low erythrocyte sedimentation rate |
B3 | Raised leukocyte alkaline phosphatase score > 100, absence of fever or infection |
B4 | Splenomegaly on ultrasound sonography |
A1 + A2 establish PV and exclude erythrocytosis. One or more of B confirm PV |
- Citation: Michiels JJ. Aspirin cures erythromelalgia and cerebrovascular disturbances in JAK2-thrombocythemia through platelet-cycloxygenase inhibition. World J Hematol 2017; 6(3): 32-54
- URL: https://www.wjgnet.com/2218-6204/full/v6/i3/32.htm
- DOI: https://dx.doi.org/10.5315/wjh.v6.i3.32